Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical testosterone for lichen sclerosus.

A Ayhan1, B Urman, K Yüce

  • 1Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Turkey.

International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|November 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reproductive surgery remains an essential element of reproductive medicine.

Facts, views & vision in ObGyn·2024
Same author

Correction to: The HERA (Hyper‑response Risk Assessment) Delphi consensus for the management of hyper‑responders in in vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

Adhesions and Anti-Adhesion Systems Highlights.

Facts, views & vision in ObGyn·2019
Same author

Platelet function testing: dead or alive.

Journal of thrombosis and haemostasis : JTH·2018

Topical testosterone effectively treated lichen sclerosus in most patients, achieving an 87.7% remission rate. Some experienced mild androgenic side effects, with a few requiring alternative therapies.

Area of Science:

  • Dermatology
  • Gynecology

Background:

  • Lichen sclerosus is a chronic inflammatory skin condition affecting the vulva.
  • Current treatments for lichen sclerosus can have varying efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical testosterone as a first-line therapy for vulvar lichen sclerosus.

Main Methods:

  • Twenty-three patients with diagnosed vulvar lichen sclerosus underwent colposcopically directed biopsy.
  • Topical testosterone was administered as the primary treatment modality.

Main Results:

  • An overall remission rate of 87.7% was observed in patients treated with topical testosterone.
  • Undesirable androgenic side effects occurred in 8.7% of patients.

Related Experiment Videos

  • Three patients did not respond adequately and received alternative treatments (alcohol injection or vulvar denervation).

    • Conclusions:

    • Topical testosterone is a highly effective first-line treatment for vulvar lichen sclerosus.
    • The therapy is generally well-tolerated, with a low incidence of androgenic side effects.
    • Alternative treatments are available for non-responsive cases.